This review critically analyzes 15+ years of microRNA (miRNA) research in cutaneous T-cell lymphoma (CTCL), covering oncogenic/tumor-suppressive networks, JAK/STAT-miRNA signaling, diagnostic classifiers, and therapeutic miRNA targeting (including Cobomarsen, an anti-miR-155 agent).
Despite extensive study, no miRNA diagnostic has reached clinical practice; the authors attribute translational stagnation to two core limitations: reliance on bulk-tissue profiling and intrinsic miRNA biology (modest, pleiotropic pathway regulation).
This is a narrative/critical review without systematic search methods or meta-analysis, so conclusions reflect expert synthesis rather than pooled quantitative evidence. No primary patient data or effect sizes are reported.
miRNA-based diagnostics and therapeutics for CTCL remain investigational; clinicians should not expect validated miRNA assays in the near term. Future advances hinge on single-cell profiling, multiomics integration, and multicenter validation studies.
Explore related topics